Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis

[1]  J. Julien,et al.  Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. , 2017, JCI insight.

[2]  J. Tapia,et al.  Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS , 2017, Proceedings of the National Academy of Sciences.

[3]  O. Hermine,et al.  ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? , 2017, Front. Aging Neurosci..

[4]  J. Julien,et al.  Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration , 2016, Neurotherapeutics.

[5]  J. Julien,et al.  From animal models to human disease: a genetic approach for personalized medicine in ALS , 2016, Acta neuropathologica communications.

[6]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[7]  R. Baruchello,et al.  Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. , 2014, Bioorganic & medicinal chemistry letters.

[8]  I. D. Hentall,et al.  Hindbrain raphe stimulation boosts cyclic adenosine monophosphate and signaling proteins in the injured spinal cord , 2014, Brain Research.

[9]  S. Sampson,et al.  Pimozide for schizophrenia or related psychoses. , 2013, The Cochrane database of systematic reviews.

[10]  Claude Gravel,et al.  Adeno-associated Virus–mediated Delivery of a Recombinant Single-chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  J. Salamone,et al.  Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor , 2013, Pharmacology Biochemistry and Behavior.

[12]  H. Neels,et al.  Therapeutic Drug Monitoring of Common Antipsychotics , 2012, Therapeutic drug monitoring.

[13]  A. Cavanna,et al.  Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. , 2012, Pediatric neurology.

[14]  J. Griffin,et al.  The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. , 2012, Genes & cancer.

[15]  J. Julien,et al.  Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. , 2011, Brain : a journal of neurology.

[16]  Y. Daali,et al.  Two structurally different T‐type Ca2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats , 2011, Fundamental & clinical pharmacology.

[17]  K. Gross,et al.  Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse , 2010, Neuroscience.

[18]  D. Rubinsztein,et al.  Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases , 2010, The Journal of Biological Chemistry.

[19]  J. Salamone,et al.  Effects of the adenosine A2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide , 2009, Neuroscience.

[20]  Wenqing Cai,et al.  Small molecule regulators of autophagy identified by an image-based high-throughput screen , 2007, Proceedings of the National Academy of Sciences.

[21]  G. Dawe,et al.  The chakragati mouse: A mouse model for rapid in vivo screening of antipsychotic drug candidates , 2007, Biotechnology journal.

[22]  D. Muller,et al.  Inhibition of T-Type Calcium Channels Protects Neurons from Delayed Ischemia-Induced Damage , 2005, Molecular Pharmacology.

[23]  J. Salamone,et al.  Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats , 2005, Pharmacology Biochemistry and Behavior.

[24]  T. McMonagle,et al.  Pimozide for schizophrenia or related psychoses. , 2000, The Cochrane database of systematic reviews.

[25]  A. Słowik,et al.  [Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes]. , 1998, Neurologia i neurochirurgia polska.

[26]  R. H. Brown,et al.  A transgenic-mouse model of amyotrophic lateral sclerosis. , 1994, The New England journal of medicine.

[27]  M. Tueth,et al.  Clinical Uses of Pimozide , 1993, Southern medical journal.

[28]  F. Sallee,et al.  Pharmacokinetics of Pimozide in Adults and Children with Tourette's Syndrome , 1987, Journal of clinical pharmacology.

[29]  A. Shapiro,et al.  Pimozide treatment of tic and Tourette disorders. , 1987, Pediatrics.

[30]  J. A. Gomes,et al.  ECG changes during haloperidol and pimozide treatment of Tourette's disorder. , 1987, The American journal of psychiatry.

[31]  E. Parati,et al.  Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[32]  R. Wise,et al.  Time course of pimozide effects on brain stimulation reward , 1983, Pharmacology Biochemistry and Behavior.

[33]  D. Calne,et al.  Tardive dyskinesia treated with pimozide , 1975, Journal of the Neurological Sciences.

[34]  W. Soudijn,et al.  Localization of [3H]pimozide in the rat brain in relation to its anti‐amphetamine potency * , 1972, The Journal of pharmacy and pharmacology.

[35]  Wei Zhou,et al.  The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation. , 2016, International journal of oncology.

[36]  D. Rubinsztein,et al.  Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. , 2006, Current topics in developmental biology.

[37]  G. Chouinard,et al.  Pimozide in the treatment of newly admitted schizophrenic patients , 2004, Psychopharmacology.